zulekha-hospital-logo

Find a doctor

Doctor's Name & Department

LOCATION SEARCH

Dr. Mehdi Afrit

Medical Doctor, Inter-University Degree (Diu) In Breast Disease

Specialist Medical Oncologist

Work Experience

  • Before joining Zulekha Hospital, Dr. Mehdi was in private practice as a Consultant Medical Oncologist from September 2017 to June 2019.
  • Previously he was associated worked with Arianna’s hospital in Tunisia as a Consultant Medical Oncologist from March 2012 to August 2017.
  • He was a faculty of medicine of Tunis in Ex Assistant hospital university from october 2012 to 2017
  • Also obtained GCP Certificate and Audit training in clinical trials and CRO (accredited from trans Celerate biopharma Inc by april 2014 and the faculty of Pharmaceutical Medicine , Royal College of Physicians in 2012) .
  • He was an Investigator in 3 International clinical Trials (ML28851/ CBC 1200.89/ EVEREXES study).
  • He have a Certificate of training on 16th course antitumor chemotherapy and cancer medical treatment at Gustave Roussy Institute Paris.
  • Dr. Mehdi is an active member of the European Society of Medical Oncology (ESMO) , member of the American Society of Clinical Oncology (ASCO), and member Tunisian Society of medical Oncology (STOM),

Languages Spoken

  • Arabic
  • English
  • French

Special Interests

  • Breast Cancer
  • Gastrointestinal Cancer
  • Gynecological Cancer
  • LUNG CANCER
  • Genitourinary Cancer

Research and Main Publications:

He had published more than 20 scientific work and research paper in international oncology and cancer journals and presented his experience in national and international conferences by meeting the expert as below:

  • PRIMARY BONE LYMPHOMA: TUNISIAN MULTICENTRIC RETROSPECTIVE STUDY ABOUT 32 CASES.Tunis Med. 2018 May;96(5):269-272.
  • FIRST SITE OF RECURRENCE AFTER BREAST CANCER ADJUVANT TREATMENT IN THE ERA OF MULTIMODALITY THERAPY: WHICH IMAGING FOR WHICH PATIENT DURING FOLLOW-UP? Breast Dis. 2017 Nov 21
  • AGGRESSIVE PRIMARY HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA: A CASE REPORT AND LITERATURE REVIEW. Cancer Biol Med. 2017 May;14(2):187-190.
  • TARGETED THERAPIES IN HER2-OVEREXPRESSING METASTATIC BREAST CANCER. Breast Care (Basel). 2016 Dec;11(6):418-422.
  • CLONAL EVOLUTIONARY ANALYSIS DURING HER2 BLOCKADE IN HER2-POSITIVE INFLAMMATORY BREAST CANCER: A PHASE II OPEN-LABEL CLINICAL TRIAL OF AFATINIB +/- VINORELBINE. PLoS Med. 2016 Dec 6;13(12).
  • AROMATASE INHIBITOR-INDUCED CARPAL TUNNEL SYNDROME: PREVALENCE IN DAILY PRACTICE.Cancer ChemotherPharmacol. 2016 Dec;78(6):1311-1315.
  • IMPLANTABLE PORT THROMBOSIS IN CANCER PATIENTS: A MONOCENTRIC EXPERIENCE Cancer Biol Med Vol 13, No 3 September 2016
  • RELAPSE PROFILE OF EARLY BREAST CANCER ACCORDING TO IMMUNOHISTOCHEMICAL SUBTYPES: GUIDANCE FOR PATIENT'S FOLLOW UP? TherAdv Med Oncol. 2015 May;7(3):144-52
  • GENOMIC CLASSIFICATION OF LUNG CANCER: TOWARD A PERSONALIZED TREATMENT. Tunis Med. 2015 Jun;93(6):339-44.
  • METASTATIC NON-SMALL CELL LUNG CANCER: A TUNISIAN RETROSPECTIVE STUDY ABOUT 100 CASES. Tunis Med. 2015 May;93
  • EXOCRINE PANCREATIC CARCINOMA IN TUNISIA: A RETROSPECTIVE STUDY ABOUT 158 CASES. Tunis Med. 2015 Feb;93(2):73-5.
  • SYNCHRONOUS PRIMARY RECTAL AND PROSTATE CANCERS. Tunis Med. 2014 Oct;92(10):648.
  • UNUSUAL AND EXTENSIVE PRESENTATION OF MERKEL CELL CARCINOMA. Tunis Med. 2014 Aug-Sep;92(8-9):581-2.
  • INFLAMMATORY BREAST CANCER IN TUNISIA FROM 2005 TO 2010: EPIDEMIOLOGIC AND ANATOMOCLINICAL TRANSITIONS FROM PUBLISHED DATA.Asian Pac J Cancer Prev. 2015;16(3):1277-80. MEDICAL THERAPIES FOR LOCALLY ADVANCED/METASTATIC KIDNEY CANCER. Presse Med. 2015 Feb;44(2):135-43.
  • AROMATASES INHIBITORS FOR BREAST CANCER IN MENOPAUSAL PATIENTS.Med. 2013 Jan;91(1):6-11.
  • STERNAL OR PARASTERNAL INVOLVEMENT FROM BREAST CANCER: A MISLEADING CLINICAL SIGN. Tunis Med. 2013 Jan;91(1):54-8.
  • HLA CLASS II SUSCEPTIBILITY TO CERVICAL CANCER AMONG TUNISIAN WOMEN. Bull Cancer. 2012 Sep;99(9):81-6.
  • CARCINOME MIXTE DE LA PROSTATE Bulletin Marocain de l’Oncologie2012 ; 2(1) :24-26
  • TRASTUZUMAB (HERCEPTIN) FOR THE MEDICAL TREATMENT OF BREAST CANCER. Tunis Med. 2012 Jan;90(1):6-12.
  • A CASE OF METASTATIC RENAL CELL CARCINOMA TREATED WITH SUNITINIB FOLLOWED BY PULMONARY RESECTIOIN
  • RITUXIMAB-INDUCED INTERSTITIAL LUNG DISEASE: CASE REPORT AND LITERATURE REVIEW. Pharmacology. 2011;87(5-6):318-20
  • SUPERIOR VENA CAVA SYNDROME AND INTERNAL MAMMARY NODES IN BREAST CANCER: TWO CASES. Tunis Med. 2011 Jan;89(1):67-9